Stock price movements
On April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its 52-week low of $118.62, and 7.03% lower than its 52-week high of $148.99.
The company’s market cap was $370.98 billion, and its PE, forward PE, price-to-sales, price-to-book, and price-to-cash multiples were 24.69x, 15.17x, 4.55x, 6.21x, and 18.84x, respectively.
Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
Analysts’ recommendations and target prices
Wall Street analysts expect an upside potential of 6.30% for Johnson & Johnson based on the company’s closing price on April 17. Analysts first raised the company’s 12-month consensus target price from $144.22 in February to $144.71 in March and then to $147.24 in April. The current consensus analyst recommendation for the stock is a “buy.”
Of the 19 analysts covering Johnson & Johnson, four have given the stock “strong buy” recommendations, six have given it “buys,” eight have given it “holds,” and only one has given it a “sell.”
In the first quarter, the company’s Consumer segment reported revenue of $3.32 billion, a YoY (year-over-year) fall of 2.4% on a reported basis. However, its revenue was up 2.2% YoY on an operational basis and 0.7% YoY on an adjusted operational basis. According to the company’s first-quarter earnings conference call, this performance was associated with its increasing share in the over-the-counter medicines market, the return of the Tylenol brand to a leading position in the analgesics market, and the robust uptake of Neutrogena and OGX in the beauty market.
In the first quarter, JNJ’s Pharmaceutical segment reported revenue of $10.24 billion, reflecting YoY rises of 4.1% on a reported basis and 7.9% on an operational and adjusted operational basis. According to the company’s first-quarter earnings conference call, this performance was driven by double-digit revenue growth in nine key products.
In the first quarter, the company’s Medical Devices segment reported revenue of $6.46 billion, reflecting YoY rises of 0.1% on a reported basis, 3.9% on an operational basis, and 5.5% on an adjusted operational basis. According to the company’s first-quarter earnings conference call, this performance was driven by robust performances in the vision, interventional solutions, and advanced surgery categories.